Marks Group Wealth Management Inc reduced its position in Boston Scientific Co. (NYSE:BSX - Free Report) by 4.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 109,241 shares of the medical equipment provider's stock after selling 4,676 shares during the period. Boston Scientific accounts for about 1.0% of Marks Group Wealth Management Inc's investment portfolio, making the stock its 21st biggest position. Marks Group Wealth Management Inc's holdings in Boston Scientific were worth $9,757,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Values First Advisors Inc. purchased a new position in shares of Boston Scientific in the third quarter valued at $28,000. Dunhill Financial LLC lifted its position in Boston Scientific by 86.4% during the third quarter. Dunhill Financial LLC now owns 328 shares of the medical equipment provider's stock valued at $28,000 after purchasing an additional 152 shares during the last quarter. Global Wealth Strategies & Associates grew its stake in shares of Boston Scientific by 423.7% in the 4th quarter. Global Wealth Strategies & Associates now owns 309 shares of the medical equipment provider's stock worth $28,000 after buying an additional 250 shares in the last quarter. West Oak Capital LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth about $29,000. Finally, E Fund Management Hong Kong Co. Ltd. purchased a new stake in shares of Boston Scientific during the 3rd quarter valued at about $30,000. 89.07% of the stock is owned by institutional investors.
Boston Scientific Stock Down 0.2 %
NYSE:BSX traded down $0.18 during mid-day trading on Wednesday, reaching $105.80. The company's stock had a trading volume of 5,456,226 shares, compared to its average volume of 6,164,861. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $155.93 billion, a PE ratio of 84.64, a price-to-earnings-growth ratio of 2.79 and a beta of 0.80. The stock has a fifty day moving average of $95.50 and a 200-day moving average of $87.72. Boston Scientific Co. has a 1 year low of $64.54 and a 1 year high of $107.17.
Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 18.11%. Equities research analysts forecast that Boston Scientific Co. will post 2.83 earnings per share for the current year.
Insider Transactions at Boston Scientific
In related news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the transaction, the director now directly owns 39,398 shares of the company's stock, valued at $3,610,038.74. This trade represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 6,528 shares of the business's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $104.97, for a total transaction of $685,244.16. Following the sale, the executive vice president now directly owns 26,449 shares in the company, valued at approximately $2,776,351.53. This represents a 19.80 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 53,830 shares of company stock valued at $5,149,969. Corporate insiders own 0.50% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts recently commented on BSX shares. JPMorgan Chase & Co. lifted their price target on Boston Scientific from $100.00 to $110.00 and gave the stock an "overweight" rating in a research report on Monday, December 16th. Truist Financial lifted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Wednesday, December 18th. UBS Group increased their price target on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a report on Friday, February 7th. StockNews.com raised shares of Boston Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, January 29th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Boston Scientific has an average rating of "Buy" and a consensus price target of $107.39.
Read Our Latest Stock Analysis on Boston Scientific
About Boston Scientific
(
Free Report)
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.
Further Reading
Before you consider Boston Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.
While Boston Scientific currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
